You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

As a result of its solid and successful experience as partner with the Italian Health System, its significant expansion into international operations and a fundamental commitment to research and development, Kedrion’s line of plasma-derived products is broad and diverse.

With treatments for many rare and debilitating diseases and conditions from hemolytic disease in newborns to immune deficiencies to hemophilia, Kedrion offers a wide and expanding array of treatments and therapies.

PRODUCT PORTFOLIO

RARE DISEASES

HEMATOLOGY / HEMOPHILIA

PLASMACLOT
Factor VIII/Von Willebrand Factor concentrate. Key number of reimbursement at "Cuadro Básico de Medicamentos": 4239 F8

KEDRIFIX
Factor IX concentrate. Key number of reimbursement at "Cuadro Básico de Medicamentos": 5238 F9
 

 

IMMUNOLOGY / NEUROLOGY

KEDRIGAMMA
Standard i.v. Immunoglobulin 5%. Key number of reimbursement at "Cuadro Básico de Medicamentos": 5244 IG5;  5240 IG6   
InmunoglobulinaHumana Normal Endovenosa. Claves del Cuadro Básico: 5244 IG5;  5240 IG6

 

MATERNAL HEALTH

RhoGAM / KeyRho
Anti-D i.m. Immunoglobulin. Key number of reimbursement at "Cuadro Básico de Medicamentos": 1591 IGD 
 

 

INTENSIVE CARE & TRANSPLANTATION

KEDRIALB
Human Albumin solution. Key number of reimbursement at "Cuadro Básico de Medicamentos": 4552 A20; 3662 A25